AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.

Animol Discovery utilizes machine learning and DNA-encoded chemical libraries to develop targeted pharmaceuticals for veterinary patients. The startup addresses the lack of effective treatment options in veterinary medicine by accelerating the discovery of safer and more effective small molecules tailored to animal health needs.

BlueWhale Bio provides the Synecta™ platform, which uses cell‑derived nanoparticle reagents to mimic natural immune activation and accelerate the expansion of CAR‑engineered and other immune‑cell therapies. The technology streamlines manufacturing, delivering more potent cell products faster and at lower cost, and is recognized as an FDA Advanced Manufacturing Technology for biotech and pharma developers of autologous cell therapies.

Enko Chem employs artificial intelligence and machine learning to develop crop protection products that minimize pesticide use while enhancing efficacy against pests and diseases. This approach addresses the urgent need for sustainable agricultural solutions by providing farmers with safer, more effective options that reduce environmental impact.

The startup offers a cloud-based research data management platform that automates workflows for biomedical research, enabling collaborative studies and machine learning applications. This platform enhances data scalability and analysis, facilitating multicenter clinical trials and accelerating the pace of scientific discoveries.

Helaxy develops fluidic cards for next-generation sequencing (NGS) library preparation, enabling clinicians to automate sample processing with minimal hands-on time. This technology eliminates manual pipetting errors and reduces reagent waste, making NGS accessible in hospitals and laboratories worldwide.

LevitasBio utilizes Levitation Technology™ for sample preparation, enabling researchers to process low-viability samples while significantly increasing cell viability and reducing contamination. This method enhances the accuracy of cellular analysis by preserving sample integrity and allowing for the enrichment of viable cells from complex biological materials.

Mercy BioAnalytics utilizes its proprietary Mercy Halo™ platform, which employs low-cost qPCR technology to detect cancer-associated biomarkers on extracellular vesicles in blood samples. This approach addresses the challenge of late cancer diagnoses by providing highly sensitive and specific tests for early-stage cancer detection, improving treatment options and patient outcomes.

Ori Biotech has developed the IRO® platform, a fully automated and standardized manufacturing system for cell and gene therapies that enhances biological performance while minimizing batch failures and reducing costs. This technology addresses the challenges of high manufacturing costs and low throughput, enabling scalable production and wider patient access to lifesaving treatments.

Orogen Therapeutics uses proprietary, AI-enabled DNA-encoded library (DEL) technology to identify novel small-molecule chemical matter against drug targets. The platform integrates DEL screening with massive chemical diversity and computation to generate enriched hit yields. The company focuses on developing oral small molecule medicines, particularly targeting cytokine pathways for immuno-inflammatory disorders.

SkylineDx develops scientifically robust and clinically relevant molecular diagnostic tests to address unmet medical needs in various diseases. Their tests analyze a patient’s unique gene expression to support care providers and patients in treatment decision-making. The company focuses on bridging the gap between biomarker discovery and commercially available diagnostic assays through strategic collaborations.